London: Scientists have found a protein that acts as a "master switch" to determine whether certain white blood cells will boost or dampen inflammation, a finding that may help the search for new drugs for rheumatoid arthritis.Many patients with rheumatoid arthritis are treated with a class of drugs known as tumor necrosis factor (TNF) inhibitors made by various drug firms including Abbott Laboratories, Merck & Co, Pfizer and AmgenBut around 30 percent of patients don`t respond to anti-TNF drugs, so experts say there is an urgent need to develop more widely effective treatment options.
"Our results show that IRF5 is the master switch in a key set of immune cells, which determines the profile of genes that get turned on in those cells," Irina Udalova, senior researcher on the study, said in a statement."This is really exciting because it means that if we can design molecules that interfere with IRF5 function, it could give us new anti-inflammatory treatments for a wide variety of conditions."The researchers said IRF5 seems to work by switching on genes that stimulate inflammatory responses and dampening genes that inhibit them.It can do this either by interacting with DNA directly, or by interacting with other proteins that themselves control which genes are switched on, they explained in their study.Udalova`s team is now studying how IRF5 works at a molecular level and which other proteins it interacts with so that they can design ways to block its effects.Rheumatoid arthritis is a chronic inflammatory disease affecting around 1 percent of the world`s population and arises when the immune system mistakenly attacks joints all over the body. As well as joints, it may also affect the skin, heart, lungs, kidneys and blood vessels. Many sufferers get deformed hands and feet, which hamper movement and ability to function.Bureau Report
Officer dies in mishap on INS Kolkata
Jagdambika Pal resigns from Congress
SC rejects Sahara`s refund proposal
Doctors` strike: Has someone from your family died? Mulayam asks mediamen